Page last updated: 2024-10-15

dibutyryl cyclic gmp

Description

Dibutyryl Cyclic GMP: N-(1-Oxobutyl)-cyclic 3',5'-(hydrogen phosphate)-2'-butanoate guanosine. A derivative of cyclic GMP. It has a higher resistance to extracellular and intracellular phosphodiesterase than cyclic GMP. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135618175
MeSH IDM0006260

Synonyms (13)

Synonym
dibutyryl 3',5'-cyclic gmp
cyclic n2-2'-0-dibutyryl-gmp
dibutyryl cyclic gmp
n(sup 2),o(sup 2)'-dibutyryl cgmp
cyclic dibutyryl gmp
dibutyryl cylic gmp
butyramide, n-(1,6-dihydro-6-oxo-9-beta-d-ribofuranosyl-9h-purin-2-yl)-, cyclic hydrogen phosphate butyrate (ester)
guanosine, n-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate
n(sup 2),o(sup 2)'-dibutyryl cyclic gmp
PDSP2_001074
PDSP1_001090
n-(9-{6-[(butanoyloxy)methyl]-2-hydroxy-2-oxotetrahydro-2h-2lambda~5~-furo[3,4-d][1,3,2]dioxaphosphol-4-yl}-6-hydroxy-9h-purin-2-yl)butanimidic acid
DTXSID40954073

Toxicity

ExcerptReference
" We examined in primary cultured hippocampal neurons whether the protein kinases PKC, PKA, CaM-II, and cGMP-dependent protein kinase modified the toxic effects of anoxia and NO."( Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia.
Boniece, IR; Maiese, K; Skurat, K; Wagner, JA, 1993
)
" Furthermore, while the toxic effect of NOR3 was attenuated by replacing the medium at 20 min, 1 or 2 h after drug addition, it was continued by replacing the medium at 3 h or later after drug addition."( Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release.
Kato, T; Nakamura, K; Yamamoto, H; Yamamoto, T; Yuyama, K, 2000
)

Compound-Compound Interactions

ExcerptReference
") infusion of urodilatin (200 ng/min) combined with dopamine (UD) to maintain mean arterial pressure could improve GFR or renal histology in established experimental ischemic acute renal failure (ARF) induced by 30 minutes of bilateral renal artery clamping; (c) assess comparative efficacies of nitroprusside, an activator of soluble guanylate cyclase, combined with dopamine (ND) or control infusions of dopamine alone (DA), under equivalent conditions; and (d) determine effects of intra-renal arterial infusions of the stable cGMP analogue dibutyryl-cGMP immediately after renal artery clamping (RAC)."( Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure.
Shaw, S; Weidmann, P; Zimmermann, A, 1992
)

Dosage Studied

ExcerptReference
" Inhibition by cAMP was achieved by shifting the Ca2+ dose-response curve for secretion to the right; this was observed for the release of both specific granules (vitamin B12 binding protein) and azurophil granules (B-glucuronidase)."( Cyclic AMP inhibits secretion from electroporated human neutrophils.
Kuczynski, B; Smolen, JE; Stoehr, SJ, 1991
)
" Schild analysis of the CCK dose-response curve indicates that L-364,718 and CR1409 exert their inhibitory effects on CCK-8-stimulated chief cell responses in a competitive manner."( Effects of CCK-receptor antagonists on CCK-stimulated pepsinogen secretion and calcium increase in isolated guinea pig gastric chief cells.
Konda, Y; Matozaki, T; Nagao, M; Nakano, O; Nishisaki, H; Sakamoto, C, 1990
)
" Dose-response curves to cholecystokinin and acetylcholine were first established."( In vitro effects of pancreatic polypeptide and motilin on contractility of human gallbladder.
Davison, JS; Pomeranz, IS; Shaffer, EA, 1983
)
" Moreover, the soluble guanylate cyclase inhibitor LY-83583 inhibited in a dose-response manner the effects of the NO donors."( The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokine-deprived human eosinophils.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
" Dose-response curves to cholecystokinin-octapeptide and carbachol were first established."( Effect of somatostatin on human gallbladder motility: an in vitro study.
Caruso, ML; Lorusso, D; Maselli, MA; Pezzolla, F; Piepoli, AL, 1999
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (532)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990302 (56.77)18.7374
1990's175 (32.89)18.2507
2000's51 (9.59)29.6817
2010's4 (0.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (1.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other545 (98.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]